# HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Source: https://onco.cc/trials/nct03850795/  
OnCo record `nct03850795` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Deutenzalutamide run by Hinova Pharmaceuticals USA, Inc., terminated.

## Summary

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT03850795 by Hinova Pharmaceuticals USA, Inc., with 104 participants enrolled, started 2021-03-15. Conditions recorded: Prostate Cancer Metastatic and Castration-resistant Prostate Cancer. Interventions recorded: HC-1119 and Enzalutamide.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03850795
- Phase: 3
- Setting: PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sponsor: Hinova Pharmaceuticals USA, Inc.
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT03850795: https://clinicaltrials.gov/study/NCT03850795

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [Deutenzalutamide](https://onco.cc/drugs/deutenzalutamide/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct03850795.json